Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-NL: Metformin for the prolongation of pregnancy in preterm preeclampsia
2023-510382-10-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of metformin in preeclampsia, HELLP syndrome (HELLP) and maternal hypertension (HDP) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Gestational prolongation. Planned start Aug 2025; status: authorised.
02
Drugs
metformin
03
Conditions
preeclampsiaHELLP syndrome (HELLP)maternal hypertension (HDP)
Beyond the preview
Go deeper on 2023-510382-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510382-10-00.